The Lynx Group
Cholangiocarcinoma News

Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations

December 2020, Vol 1, No 3

At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.

Kenna R. Mills Shaw, PhD, Executive Director, Khalifa Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center, Houston, pointed out the difficulties in operationalizing precision medicine.

“We see over 100,000 patients a year and we perform over 20,000 molecular tests across our leukemia and solid tumor patient populations. When we started to look very discreetly at the number of molecular results that were utilized for treatment decisions in our patient population a few years ago, we found that it was a very small number of patients,” Dr Mills Shaw said.

“On a 46- and 50-gene hotspot panel, when we looked at 2000 patients that were not getting tested for standard of care but were looking for clinical trial opportunities, we found that only about 4% of our patient population overall—4% of the 2000—or just about 11% of the patients with a mutation and an actionable gene, were ultimately matched to a therapeutic target. This is, of course, concerning to us, as we wanted to try to inform or push forward precision medicine,” Dr Mills Shaw added.

She cautioned that regardless of how much of the genomic landscape is being sequenced, oncologists are still working with only a very small amount of an actionable genome. Her advice for oncologists is to make sure that they understand what’s being tested, what’s on the panel, what’s not on the panel, and what’s not included in the assay so the data can be properly interpreted.

Next-Generation Sequencing in Cholangiocarcinoma

Afsaneh Barzi, MD, PhD, Clinical Medical Director, Access Hope, and Associate Professor, Clinical Medicine-Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, focused her discussion on next-generation sequencing in cholangiocarcinoma (CCA) and the challenges in interpreting these data.

“My own sense is that it’s just not enough to say what we see on these reports. It’s also important to know what we’re not seeing on these reports, and whether that requires additional testing, or whether we should pay attention to what is unknown. It’s important to familiarize yourself with the report you’re commonly using,” Dr Barzi said.

She highlighted the importance of fusions and translocations as drivers in CCA. Maximizing the detection of such fusions enhances the benefit of precision medicine for various solid tumors. However, Dr Barzi noted that DNA-based next-generation sequencing can miss some fusions.

“The majority of these missed fusions were actionable. This only tells us that by looking at the DNA only, you may be actually missing some of these fusions. As clinicians, we have to be aware of it and look at alternatives to answer a clinical question,” Dr Barzi advised.

She emphasized that maximizing the rate of variant diagnosis for targeted therapy relies on precise identification of common and rare fusions. RNA sequencing yields information beyond what conventional DNA next-generation sequencing alone can provide. The addition of RNA sequencing will enhance the detection of targetable fusions and translocations in patients with intrahepatic CCA, she said.

“Don’t be satisfied with the results if you think there is something that can change the outcome. Always reach out to the labs who are doing the tests. They have resources that can help with interpretation of the results,” Dr Barzi concluded.

Related Items

Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Gallbladder Cancer: Novel Approaches to Therapy Are Needed
December 2020, Vol 1, No 3
The current standard of care for the systemic treatment of patients with advanced gallbladder cancer is the chemotherapy combination of gemcitabine and cisplatin, which is suboptimal, yielding only modest benefit, said Richard Kim, MD, Section Chief, Gastrointestinal Medical Oncology, Moffitt Cancer Center, Tampa, FL, at the 2020 Cholangiocarcinoma Summit.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
Improving Chemotherapy Combinations and Novel Treatments Are Needed in Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
New cytotoxic chemotherapy regimens and novel combinations are being evaluated in clinical trials in an effort to improve the outcomes of chemotherapy in the adjuvant and palliative settings in patients with biliary tract cancer, including cholangiocarcinoma (CCA), said Angela Lamarca, MD, PhD, MSc, Consultant, Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom. She discussed the future of cytotoxic chemotherapy for this patient population at the 2020 Cholangiocarcinoma Summit.
Role of Liver Transplant in Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Liver transplant is emerging as a treatment option in patients with unresectable hilar or intrahepatic cholangiocarcinoma (CCA), with accumulating data supporting transplant protocols in patients with early-stage CCA.
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Zanidatamab Addresses an Unmet Need in Patients with HER2-Amplified Biliary Tract Cancer
December 2020, Vol 1, No 3
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the HER2 receptor) HER2-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the HER2 receptor.
Increasing Number of Biomarkers Being Studied in Cholangiocarcinoma Clinical Trials
December 2020, Vol 1, No 3
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Telotristat Ethyl and First-Line Chemotherapy Combination Investigated for Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
The metabolism of serotonin is dysregulated in cholangiocarcinoma (CCA) cell lines compared with normal cholangiocytes and in tissue and bile from patients with CCA.1 Telotristat ethyl (Xermelo) is a tryptophan hydroxylase inhibitor that is indicated for the treatment of patients with carcinoid syndrome–related diarrhea not well-controlled by somatostatin analog. Telotristat ethyl is currently being investigated for the treatment of patients with biliary tract cancer, including CCA tumors that express serotonin.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: